From ImmusanT Press Release 20 October 2018 Cambridge, MA “CAMBRIDGE, Mass. – October 30, 2018 – ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, initiated enrollment in Australia and New Zealand for its Phase 2 RESET CeD study […]
